WallStSmart

Iradimed Co (IRMD)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 41026% more annual revenue ($35.48B vs $86.28M). IRMD leads profitability with a 27.4% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.29. MDT earns a higher WallStSmart Score of 61/100 (C+).

IRMD

Buy

61

out of 100

Grade: C+

Growth: 7.3Profit: 9.5Value: 3.0Quality: 7.3
Piotroski: 3/9Altman Z: 7.18

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IRMD.

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRMD5 strengths · Avg: 9.2/10
Operating MarginProfitability
32.9%10/10

Strong operational efficiency at 32.9%

Altman Z-ScoreHealth
7.1810/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

EPS GrowthGrowth
22.1%8/10

Earnings expanding 22.1% YoY

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

IRMD4 concerns · Avg: 3.0/10
Price/BookValuation
12.1x4/10

Trading at 12.1x book value

Market CapQuality
$1.18B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.462/10

Expensive relative to growth rate

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : IRMD

The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 32.9%. Revenue growth of 12.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : IRMD

The primary concerns for IRMD are Price/Book, Market Cap, Piotroski F-Score. A P/E of 50.3x leaves little room for execution misses.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

IRMD profiles as a mature stock while MDT is a value play — different risk/reward profiles.

IRMD carries more volatility with a beta of 0.91 — expect wider price swings.

IRMD is growing revenue faster at 12.6% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

IRMD scores higher overall (61/100 vs 61/100), backed by strong 27.4% margins and 12.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Iradimed Co

HEALTHCARE · MEDICAL DEVICES · USA

IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?